Loading
TQB2930 is an experimental bispecific antibody from Chia Tai Tianqing Pharmaceutical in phase 2 trials for HR-positive / HER2-negative breast cancer, aimed at HER2 and EGFR.
TQB2930 is a bispecific antibody developed by Chia Tai Tianqing Pharmaceutical and Chia Tai Tianqing Pharmaceutical Nanjing Shunxin Pharmaceutical. Its targets are HER2 and EGFR (the sponsor names HER2). The sponsor states: TQB2930 is a HER2 bispecific antibody given by intravenous infusion, being studied as monotherapy or combination therapy in HER2-positive recurrent/metastatic breast cancer. ClinicalTrials.gov describes the intervention as: TQB2930 for injection is a HER2 bispecific antibody. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, in HR-positive / HER2-negative breast cancer. The largest, NCT07512583, plans to enrol 178 participants with primary completion expected 2028-03. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
1.One arm of TQB2930 binds HER2 on the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"TQB2930" OR ABSTRACT:"TQB2930") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about TQB2930, not a curated reading list.
Shares A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer, Sino Biopharmaceutical (Chia Tai Tianqing), HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Clinical Studies of TQB2930 Injection for the Treatment of Advanced Solid Tumors, Sino Biopharmaceutical (Chia Tai Tianqing), HER2, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Sino Biopharmaceutical (Chia Tai Tianqing), EGFR and the tag pipeline.
Shares Sino Biopharmaceutical (Chia Tai Tianqing), EGFR and the tag pipeline.